ÂÜÀòÂÒÂ×

Jessica Wolfe, MBA has extensive experience in the pharmaceutical industry, focusing on government affairs and advocacy. Jessica is currently serving as the Head of Pipeline Patient Advocacy and Engagement at Jazz Pharmaceuticals, where they are responsible for ensuring access to life-changing medicines for patients facing serious and rare diseases. Prior to this role, they served as the Head of Corporate Sustainability and Social Impact at Jazz Pharmaceuticals, leading efforts to embed purpose and passion into the company's operations.

Before working at Jazz Pharmaceuticals, Jessica held various positions at Greenwich Biosciences, including Senior Director of State Government Reimbursement and Policy. Jessica played a key role in bringing the first botanically derived cannabis medication for severe pediatric epilepsy to market in the U.S. Additionally, they worked as the Director of Payer Advocacy and Government Affairs at SCILEX Pharmaceuticals Inc., and as the Director of Government Affairs and Advocacy at inVentiv Health.

Jessica also has experience in legislative advocacy and lobbying, having served as the Principal Owner of JW Strategies LLC, where they directed targeted campaigns to advance clients' interests and increase awareness of healthcare policy initiatives and government programs. Jessica has also worked at Boston Scientific as Manager of State Government Relations and served as a Special Assistant to Cabinet Affairs for New Mexico Governor Bill Richardson.

Early in their career, Jessica worked as a Professional Sales Representative at Boehringer Ingelheim and as a Clinical Specialist at Medtronic. Jessica holds an MBA degree and has a strong background in healthcare policy and government relations.

Jessica Wolfe completed their Bachelor's Degree in Political Science and Communication Studies at Vanderbilt University from 1998 to 2002. During the same period, they also majored in Communication Studies and Political Science for their Bachelor of Science degree. In 2021, Jessica enrolled at the University of Denver and obtained their Master of Business Administration (MBA) degree in Business Administration and Management, General in 2022.